D&D Pharmatech Appoints Yoo-Seok Hong as Chief Executive Officer

2021-06-16

D&D Pharmatech Appoints Yoo-Seok Hong as Chief Executive Officer

  • GSK veteran brings decades of commercial expertise as D&D advances pipeline of clinical candidates for neurodegenerative diseases and fibrosis

GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--()--D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, today announced the appointment of Yoo-Seok Hong as Chief Executive Officer. Mr. Hong will assume this role on July 1, 2021.

“D&D is entering a pivotal period of growth as we pursue the clinical potential of a robust pipeline of clinical assets. I look forward to working closely with the leadership team to help bring new therapies to patients around the world.

Most recently, Mr. Hong served as GSK’s Vice President, Medicine Commercialization Leader Linerixibat and prior to that role, served as the President of GSK Canada. Mr. Hong brings nearly three decades of experience in the biopharmaceutical industry to his new role with D&D Pharmatech. He has held various senior commercial and strategic leadership roles at GSK, Teva and Lilly including general manager roles in Korea, a senior strategic leadership role in emerging markets, and was responsible for international marketing leadership of Lilly’s osteoporosis brands.

“Yoo-Seok is a strategic leader with decades of experience in commercializing and managing the product lifecycle of innovative drugs in Korea, Canada, U.S., Europe, China and many emerging markets,” said Dr. Seulki Lee, founder and Chairman of D&D. “We look forward to Yoo-Seok’s leadership as we advance our pipeline of clinical candidates toward critical data readouts and commercialization.”

Neuraly, D&D’s subsidiary company is currently conducting a Phase 2 clinical trial of NLY01 in Parkinson’s disease and entering Phase 2B for patients with Alzheimer’s disease. Earlier this year, D&D announced dosing of the first patient in its Phase 1 clinical trial of DD01 for obese patients with diabetes and non-alcoholic fatty liver disease (NAFLD).

“I’m excited to join D&D at this important time in the company’s evolution,” said Mr. Hong. “D&D is entering a pivotal period of growth as we pursue the clinical potential of a robust pipeline of clinical assets. I look forward to working closely with the leadership team to help bring new therapies to patients around the world.”

About D&D Pharmatech

D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The company’s product pipeline focuses on a range of indications including neurodegenerative, fibrotic and metabolic diseases. D&D Pharmatech is the parent company of U.S.-based Neuraly Inc., Theraly Fibrosis Inc., Precision Molecular Inc., Valted Seq Inc, and P4Microbiome. For more information, please visit http://www.ddpharmatech.com/

Contacts

Media Contact:
Christine Quern
CBQ Communications
cq@christinequern.com
617.650.8497

D&D PHARMATECH, INC.